MP18-05 IS SALVAGE FOCAL CRYOTHERAPY CURATIVE TREATMENT FOR PATIENTS WITH LOCALIZED RECURRENT PROSTATE CANCER?

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy1 Apr 2016MP18-05 IS SALVAGE FOCAL CRYOTHERAPY CURATIVE TREATMENT FOR PATIENTS WITH LOCALIZED RECURRENT PROSTATE CANCER? Courtney J. Berg, Kaitlin E. Kosinski, and Aaron E. Katz Courtney J. BergCourtney J. Berg More articles by this author , Kaitlin E. KosinskiKaitlin E. Kosinski More articles by this author , and Aaron E. KatzAaron E. Katz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2706AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The salvage therapy options for patients with recurrent unilateral prostate cancer after primary radiation, or cryotherapy are limited. Salvage focal cryotherapy is becoming a more popular treatment option as it has shown success in its disease free survival rates. Salvage focal cryotherapy enables patients to delay or negate the use of hormone therapy which has many unfavorable adverse effects. The aim of this study is to report on the curative success of salvage focal cryotherapy in recurrent unilateral prostate cancer patients. METHODS We identified patients that underwent salvage focal cryotherapy at Winthrop University Hospital between February 2011 and August 2015. Age at the time of treatment, follow up time, nadir PSA levels and follow up treatments were assessed. RESULTS From 2011 to 2015, 88 patients underwent salvage focal cryoablation. Of these patients, 14 (15.9%) required another therapy treatment after salvage focal cryoablation. Hormone therapy was a necessary treatment for 9 patients. Only 6 patients (6.8%) went on to hormone therapy due to an MRI finding of a local, nodal, or distant relapses. Three (3.4%) patients went on to hormone therapy due to a rise in PSA. CONCLUSIONS Focal salvage therapy is associated with very low risk of clinical and radiographic progression of cancer. In our patients with radiation recurrent cancer we were able to prevent or delay the use of hormone therapy in the majority of these men. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e194 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Courtney J. Berg More articles by this author Kaitlin E. Kosinski More articles by this author Aaron E. Katz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...